New developments in antifungals

International Journal of Dermatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 65-69

  Hay, Roderick J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BIFONAZOLE; BMS 181184; CASPOFUNGIN; FLUCONAZOLE; GENACONAZOLE; ITRACONAZOLE; LY 743872; NYSTATIN; POSACONAZOLE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; SAPERCONAZOLE; TERBINAFINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN TISSUE; MYCOSIS; NEPHROTOXICITY; TREATMENT INDICATION;

EID: 0032886484     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00013.x     Document Type: Article

References (30)

1. Evans EG, Seaman RA, James IG. Short-duration therapy with terbinafine i % cream in dermatophyte skin infections. Br J Dermatol 1994; 130: 83-87.
2. Miller R, Bates JH. Amphotericin B toxicity. A follow up report of 53 patients. Ann Intern Med 1969; 71: 1090-1095.
3. Rex JH, Bennett JE, Sugar AM et al. A randomised trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Eng J Med 1994; 331:1325-1330.
4. Dupont B. Antifungal therapy in AIDS patients. In: Bennett JE, Hay RJ, Peterson PK, eds. New Strategies in Fungal Disease. Edinburgh: Churchill Livingstone, pp 290-300; 1992.
5. Evans EG. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998; 38: S32-S36.
6. Andriole VT. Aspergillus infections: problems in diagnosis and treatment. Infect Ag Dis 1996; 5: 47-54.
7. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11: 415-419.
8. Elewski B. Cutaneous mycoses in children. Br J Dermatol 1996; 134 (Suppl. 46):7-11.
9. Van Den Bossche H, Dromer F, Improvisi I, et al. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 (Suppl. 1): 119-128.
10. Denning DW. Invasive aspergillosis in immunocompromised patients. Curr Opin Infect Dis 1991; 7:456-462.
11. Savin R, De Villez RL, Elewski B, et al. One-week therapy with twice-daily butenafine 1 % cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. J Am Acad Dermatol 1997; 36: S15-S19.
12. Fu KP, Isaacson DM, Lococo J, et al. In vitro and vivo antidermatophytic activity or saperconazole, a new fluorinated triazole. Drugs Exp Clin Res 1991; 18: 443-446.
13. Anaissie EJ, Kontoyiannis DP, Vartivarian S, et al. Effectiveness of an oral triazole for opportunistic mold infection in patients with cancer: experience with SCH 39304. Clin Infect Dis 1993; 17: 1022-1033.
14. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK 109496) a new triazole antifungal agent, against emerging and less common mould pathogens. Antimicrob Ag Chemother 1997; 41: 841-843.
15. Galgiani JN, Lewis ML. In vitro studies of the antifungal triazoles, SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans and other pathogenic yeasts. Antimicrob Ag Chemother 1997; 41: 180-183.
16. Pfaller MA, Messer SA, Coffman S. Comparison of visual and spectrophotometric methods for MIC endpoint detreminations by using broth microdilution methods to test five antifungal agents inclduing the new triazole D0870. J Clin Microbiol 1995; 33: 1094-1097.
17. Pfaller MA, Messer S, Coffman S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative LY 303366 and other antifungal agents. Antimicrob Ag Chemother 1997; 41: 763-766.
18. Abbruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589 and L-731373 in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob Ag Chemother 1995; 39:1077-1081.
19. Hector RF, Zimmer BL, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis and balstomycosis. Antimicob Ag Chemother 1990; 34: 587-593.
20. Fung-Tomc JC, Minassian R, Huczko E, et al. In vitro antifungal and fungicidal spectra of a new pradimicin deribative BMS-181184. Antimicrob Ag Chemother 1995; 39: 295-300.
21. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte macrophage colony stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705-707.
22. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B incorporated in liposomes (Ambisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Ag Chemother 1991; 28 (Suppl. B): 73-82.
23. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995; 21: 1145-1153.
24. Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997; 20: 39-43.
25. Schoffski P, Freund M, Wunder R, et al. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 1998; 317: 379-384.
26. Johnson EM, Ojwang JO, Szekely A, et al. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Ag Chemother 1998; 42: 1412-1416.
27. Ryder NS, Letitner I. Activity of terbinafine against Aspergillus in vitro in combination with amphotericin B or triazoles. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract E 54, 91. Washington, DC: Am. Soc. Microbiol; 1996.
28. Baran R, de Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Dermato-Venereol 1996; 76: 82-83.
29. Roberts DT, Evans EG. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998; 138: 189-190.
30. Graser Y, El Fari M, Presber W, et al. Identification of common dermatophytes (Trichophyton, Microsporum, Epidermophyton) using polymerase chain reactions. Br J Dermatol 1998; 138: 576-582.